Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.01
-0.7100-0.23%
Volume:38.63K
Turnover:12.05M
Market Cap:18.72B
PE:33.76
High:313.00
Open:313.00
Low:310.78
Close:311.72
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.83
T/O Rate:0.06%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.49

Loading ...

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Exchange-Traded Funds, US Equities Decline After Midday

MT Newswires Live
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23

New Model-Based Analysis Further Supports the Potential of Tecvayli® (Teclistamab-Cqyv) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) to Redefine Long-Term Survival Expectations in Early Line Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 23

J&J - Analysis Estimates 87% of Tecvayli Plus Darzalex Faspro Patients Have Comparable Mortality Risk to General Population

THOMSON REUTERS
·
Sep 23

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug

Reuters
·
Sep 23

MeiraGTx Appoints Veteran Investor Alan Sebulsky to Board

TIPRANKS
·
Sep 23

TD Cowen Adjusts Merck Price Target to $155 From $137, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Want to Bet on Risky, High-Beta Stocks? Why You Should Wait for Mid-October

Dow Jones
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Kimberly-Clark Offers Remedies in Bid for EU Approval of Kenvue Deal

Reuters
·
Sep 23

Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT

Reuters
·
Sep 23

Merck & Co Inc : TD Cowen Raises Target Price to $155 from $137

THOMSON REUTERS
·
Sep 23

Vance-Led Task Force Removing 760,000 Allegedly Fraudulent Obamacare Enrollments

Dow Jones
·
Sep 23